Scientists hunt for clues to stop corneal graft rejection

NCT ID NCT05009407

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examined whether a protein called CD160 appears in new blood and lymph vessels that grow in the cornea after a transplant. Researchers analyzed tissue from 43 patients who had corneal transplant surgery. The goal was to see if CD160 is linked to graft rejection, which could lead to better treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If CD160 is found in corneal vessels, it could point toward new ways to prevent graft rejection.

What could go wrong

This is a small, completed observational study analyzing tissue samples. It does not test any treatment, so any future applications are uncertain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOGENESIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Damien JOLLY

    Reims, France